All IndicationsOncology
🎗️
Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
1
Companies
1
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| INTI Intitute (or manufacturer of ABECMA) | ABECMA | — | — | — | — |
Development Stage Distribution
Unknown
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.